Avidity Partners Management LP Lowers Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Avidity Partners Management LP reduced its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 1.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,873,000 shares of the company's stock after selling 44,231 shares during the period. Dianthus Therapeutics makes up 6.2% of Avidity Partners Management LP's portfolio, making the stock its biggest holding. Avidity Partners Management LP owned about 9.71% of Dianthus Therapeutics worth $62,631,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. R Squared Ltd bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth approximately $26,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at $33,000. KBC Group NV purchased a new position in Dianthus Therapeutics in the fourth quarter worth $35,000. BNP Paribas Financial Markets bought a new position in Dianthus Therapeutics in the fourth quarter valued at $59,000. Finally, AlphaQuest LLC raised its position in Dianthus Therapeutics by 273.1% during the fourth quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock valued at $91,000 after purchasing an additional 3,072 shares in the last quarter. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Price Performance

DNTH stock traded down $1.00 during midday trading on Friday, hitting $19.62. The stock had a trading volume of 145,101 shares, compared to its average volume of 265,957. Dianthus Therapeutics, Inc. has a 52-week low of $13.37 and a 52-week high of $32.27. The firm has a market cap of $630.31 million, a price-to-earnings ratio of -7.85 and a beta of 1.48. The business has a 50-day moving average of $19.84 and a two-hundred day moving average of $22.50.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($0.85) by $0.04. The business had revenue of $1.33 million for the quarter, compared to analysts' expectations of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

DNTH has been the subject of a number of recent research reports. HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Wedbush reiterated an "outperform" rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $54.33.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.